US Corporate Board Director Changes SEC Filings — July 09, 2026

09-07-2026

Eos Energy Enterprises appointed Haiyan Song to its Board of Directors and named Marie Batz Martin as Chief Legal Officer effective July 13, 2026, as part of a planned leadership transition. Greg Nixon stepped down as preferred stock director, with Nate Fick moving into that role and Song filling Fick's independent director seat. The changes strengthen the company's governance and technology expertise as it scales U.S. manufacturing and commercial deployments, though no financial metrics or performance data were disclosed in the filing.

• · Haiyan Song brings over 30 years of experience in software, cloud, cybersecurity, and enterprise technology, most recently as EVP of NetApp's CloudOps business.
• · Marie Martin has over 20 years of legal, compliance, and governance leadership at global industrial companies, most recently as Global VP and Chief Compliance Officer at Coherent Corp.
• · Michael Silberman will remain as a non-executive employee through September 11, 2026, to support the transition.
• · The size of the Board, number of independent directors, and number of preferred stock directors remain unchanged after the transitions.

09-07-2026

United Natural Foods (UNFI) announced leadership changes effective August 3, 2026, to accelerate its value creation strategy. Matteo Tarditi will become President and COO, Louis Martin will serve as Chief Commercial Officer, and Alfredo Luchini will join as CFO on August 10, 2026. Concurrently, President Mark Bushway will leave the company on January 1, 2027, after a transition period. The moves aim to strengthen commercial capabilities and operational execution, though the departure of a 23-year veteran introduces execution risk.

• · Leadership changes effective August 3, 2026, except CFO Luchini who starts August 10, 2026.
• · Mark Bushway will leave UNFI on January 1, 2027, after a 23-year career.
• · Tarditi will oversee product sales, customer relationships, supply chain, technology, and lean implementation.
• · Martin will focus on merchandising, supplier partnerships, private brands, and digital services.
• · Luchini previously led finance for an $11B business segment at Carrier Global Corporation.
• · UNFI serves approximately 30,000 retail locations across North America.

09-07-2026

Align Technology announced the resignation of Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer, effective August 1, 2026, to join Illumina, Inc. as Chief Legal Officer. The departure represents a loss of a key executive but is not accompanied by any financial metrics or performance data.

• · Julie Coletti's resignation is effective August 1, 2026.
• · She is leaving to become Chief Legal Officer at Illumina, Inc.
• · The filing does not disclose any interim replacement or succession plan.

09-07-2026

Enovix appointed Dr. Michael Vyvoda, former Apple Director of Product Operations, as COO effective July 29, 2026, to lead global manufacturing ramp across Malaysia, Korea, and India. The company reported Q1 2026 revenue of $7.6M, up 49% YoY, with its sixth consecutive quarter of positive gross profit and a global pipeline for Korea-manufactured products exceeding $130M. However, the company continues to scale from a loss-making history and faces risks in achieving high-volume production and customer qualification.

• · Michael Vyvoda holds a Ph.D. in Chemical Engineering from UC Berkeley and a B.S. from University of Michigan.
• · He previously served as COO at Magrathea Metals and Aircapture, and spent over five years at Apple as Director, Product Operations for Audio Products.
• · Enovix's first commercial production order for smart eyewear battery is approximately 50,000 units.
• · The company recently launched the MX-1 platform for drone and defense markets.
• · Enovix has manufacturing facilities in Korea and Malaysia, and R&D operations in India.

09-07-2026

Philip Morris International Inc. (PM) announced the departure of CFO Emmanuel Babeau, effective August 1, 2026, with Massimo Andolina succeeding him. Babeau will remain as Strategic Advisor to the CEO through March 31, 2027, and entered into a Separation Agreement providing continued base salary of CHF 1,260,012 ($1,563,423), eligibility for 2026 annual cash incentive (125% of base salary), a restricted portion of the 2027 equity award, and post-employment severance including a lump sum equal to his base salary and CHF 393,754 ($488,570) in lieu of pro-rated 2027 incentive, plus full vesting of outstanding equity awards. The agreement includes a 24-month non-compete clause and customary confidentiality provisions.

• · Emmanuel Babeau's employment as Strategic Advisor ends March 31, 2027 (Separation Date).
• · The 2027 equity award eligibility is limited to the RSU portion (40% of total otherwise eligible), subject to Board approval.
• · Post-employment severance includes full vesting of all then-outstanding equity awards.
• · The Separation Agreement includes a general release of claims and is conditioned on continued employment through the Separation Date.

09-07-2026

Medline Inc. announced the retirement of Chief Operating Officer Stephen L. Miller, effective August 30, 2026, due to health reasons. The company has initiated a search for his successor. No financial metrics or performance data were disclosed in this filing.

• · Retirement effective date: August 30, 2026
• · Reason for retirement: health-related
• · Successor search is ongoing

09-07-2026

Angi Inc. announced the resignation of Chief Accounting Officer Austin Kaplicer, effective August 6, 2026, to pursue an opportunity in a different industry. The company promoted Scott Jakalow to Chief Accounting Officer and designated CFO Julie Hoarau as principal accounting officer. No financial figures or performance metrics were disclosed in this filing.

• · Austin Kaplicer's resignation is effective August 6, 2026, and he will remain to oversee Q2 2026 earnings materials and the Form 10-Q.
• · Scott Jakalow is promoted to Chief Accounting Officer effective August 6, 2026.
• · Julie Hoarau, CFO, is designated as principal accounting officer effective August 6, 2026.
• · Kaplicer's resignation is not due to any disagreement with the company regarding financial statements, internal controls, operations, policies, or practices.

09-07-2026

enCore Energy Corp. entered into a Separation Agreement with former CEO Robert J. Willette, who was terminated without cause effective April 20, 2026. He will receive a cash payment of $1,800,000 and a grant of 300,000 immediately-vesting nonqualified stock options for consulting services, while forfeiting all other unvested equity awards. The agreement was finalized on July 8, 2026.

• · Mr. Willette's termination was without cause and not due to any disagreement with the company on operations, policies, or accounting practices.
• · The Consulting Options have a five-year term and an exercise price equal to the closing price on the grant date.
• · In addition to forfeiting all other unvested stock options and RSUs, Mr. Willette will bear his own documented attorneys' fees from the cash payment.
• · The Separation Agreement was effective July 8, 2026, nearly three months after the termination date.

09-07-2026

First Interstate Bancsystem Inc. (FIBK) announced the involuntary termination without cause of Kirk D. Jensen as Executive Vice President, General Counsel, and Corporate Secretary, effective July 9, 2026. The company will conduct a national search for a replacement, with in-house lawyers handling the role in the interim. The termination is not related to any disagreement over financial reporting, operations, or policies.

• · The termination is involuntary and without cause under Jensen's employment agreement.
• · The employment agreement was filed as an exhibit to the company's most recent Form 10-K (filed Feb 26, 2026).
• · The company explicitly states the termination is not due to any disagreement over financial reporting, operations, policies, or practices.

09-07-2026

Traws Pharma, Inc. held its 2026 Annual Meeting on July 8, 2026, where stockholders approved all five proposals, including the election of seven directors, an amendment to the 2021 Incentive Compensation Plan to increase authorized shares by 2,000,000, ratification of KPMG LLP as auditor, and the issuance of shares upon exercise of Series B and C Warrants. The meeting saw a quorum of 55.78% of outstanding shares represented. While all proposals passed, Proposal 2 (compensation plan amendment) received a notable 26.0% 'against' vote (1,694,075 votes against vs. 4,821,796 for), indicating some shareholder dissent.

• · Proposal 3 (ratification of KPMG) received 7,659,805 votes for and 789,757 against, with no broker non-votes.
• · Proposal 4 (warrant exercise shares) passed with 2,270,414 votes for, 151,196 against, and 614,528 abstentions, excluding 3,486,423 shares per Nasdaq rules.
• · Proposal 5 (adjournment) was approved but not needed as all other proposals passed.
• · The record date for the meeting was May 18, 2026.
• · Shares issued to certain investors under the April 15, 2026 Securities Purchase Agreement were not entitled to vote on Proposal 4.

09-07-2026

Southern California Gas Company (SoCalGas) announced a series of senior leadership changes on July 6, 2026, including the appointment of Karen L. Sedgwick as CEO and President (effective Q3 2026), Ross W. Turrini as COO (effective August 10, 2026), and Elvia Lima Ortiz as VP, Chief Accounting Officer, Controller and Assistant Treasurer (effective July 10, 2026). These appointments follow the planned retirement of Rodger R. Schwecke and the resignation of Sara P. Mijares, who will receive a $315,000 cash payment and severance benefits. The new officers will receive compensation packages including base salaries of $830,000 (Sedgwick), $500,000 (Turrini), and $255,000 (Lima Ortiz), along with various incentive and retention payments.

• · Sedgwick's appointment as CEO is effective on a date to be determined in Q3 2026; she will also receive a $200,000 relocation incentive for each of her first two years.
• · Turrini's COO appointment is effective August 10, 2026; he will receive a one-time RSU award of $500,000 with a three-year vesting schedule (20%, 40%, 40%) and cash retention payments totaling up to $800,000 over three years, plus a $200,000 transition support payment.
• · Lima Ortiz's appointment as VP/CAO is effective July 10, 2026; her target long-term equity award is 80% of base salary.
• · Mijares will resign effective July 9, 2026, and remain in an advisory capacity through July 24, 2026; she will receive severance benefits and a $315,000 cash payment for forfeited equity awards.
• · Schwecke will serve as Executive Advisor until his retirement on October 1, 2026.

09-07-2026

Sempra appointed Justin C. Bird as Executive Vice President and Chief Financial Officer, effective around the closing of its planned sale of a portion of its equity interest in Sempra Infrastructure Partners, expected in Q3 2026. Concurrently, Karen L. Sedgwick will become CEO and President of Southern California Gas Company. Mr. Bird's compensation is not expected to change with this appointment.

• · Mr. Bird, 55, has served in various leadership roles across Sempra for over two decades, most recently as Executive Vice President since January 2024 and CEO of Sempra Infrastructure since April 2020.
• · Mr. Bird's compensation is not expected to change in connection with this appointment.
• · The effective date of Mr. Bird's CFO appointment is tied to the closing of the planned sale of a portion of Sempra's equity interest in Sempra Infrastructure Partners, expected in Q3 2026.
• · Karen L. Sedgwick's appointment as CEO and President of Southern California Gas Company is concurrent with Mr. Bird's effective date.

09-07-2026

Paycom Software, Inc. appointed Craig Boelte (former CFO) and William Kerber (former CIO) to its board of directors, effective July 8, 2026, expanding the board from six to eight members. Both appointees have deep ties to the company, with Boelte having served as CFO for nearly 20 years and Kerber being one of the original employees and former CIO. The appointments bring extensive industry and operational experience, though no immediate financial impact or change in strategy was disclosed.

• · Boelte was instrumental in Paycom's transition to a public company in 2014 and subsequent revenue growth from $108M in 2013 to approaching $2B prior to his retirement in 2025.
• · Kerber was one of the original employees of Paycom, starting in 1999, and served as CIO from 2007 to 2017.
• · Kerber is currently CEO of Human Mode, LLC, a robotics company.
• · Boelte serves on the board of Kirkpatrick Bank.

09-07-2026

Christopher M. Smith resigned from the board of directors of Pacific Biosciences of California, Inc. (PACB) effective July 8, 2026. The company stated that his resignation was not due to any disagreement with the company's operations, policies, or practices. No replacement or further board changes were announced.

• · Resignation effective immediately as of July 8, 2026.
• · No disagreement cited between Mr. Smith and the company.
• · No successor or interim director announced.

09-07-2026

FuboTV Inc. announced the appointment of Alisa Bowen, former president of Disney+, as CEO effective July 10, 2026, succeeding co-founder David Gandler. Bowen brings nearly 30 years of media and streaming experience, including leadership at Disney+, Hulu, and ESPN+. The filing notes the company's strategic evolution following the Hulu + Live TV combination but does not provide any financial metrics or performance data.

• · Bowen's appointment is effective July 10, 2026.
• · Bowen is expected to be appointed to the Board subject to approval after the Annual Meeting of Stockholders on July 28, 2026.
• · David Gandler has resigned from the Board and will not stand for re-election.
• · FuboTV is described as the sixth largest Pay TV company in the U.S. (per UBS estimates).
• · FuboTV was ranked among Fast Company's Most Innovative Companies (2026) and Financial Times' The Americas' Fastest-Growing Companies (2026, 2025).

09-07-2026

On July 7, 2026, Park Aerospace Corp. terminated Cory Nickel as Senior Vice President and General Manager, effective immediately, and appointed John Jamieson, age 65, to the same role. Jamieson had served as SVP of Project Management since July 2024. The Board approved an increase in his annual base salary from $193,000 to $205,000, effective July 13, 2026. No family relationships or disclosable transactions were noted.

• · John Jamieson previously served as Senior Vice President of Project Management at Park Aerospace Corp. since July 30, 2024.
• · Prior roles include COO of Active Dynamics Group (2018-2022), VP of Supply Chain at Park Aerospace (2014-2018), GM of Active Metals Company (2012-2013), and VP of Global Manufacturing and Engineering at Sanmina Corporation (2003-2012).
• · Jamieson holds a Bachelor’s Degree in Mechanical Engineering from James Watt College in the United Kingdom.

09-07-2026

Reinsurance Group of America (RGA) disclosed compensation adjustments for its newly appointed CFO, Laura Cockrill, effective July 2, 2026. Her annual base salary was increased to $650,000, with an Annual Bonus Plan target of 175% of base salary and a long-term incentive target of 300% of base salary. Additionally, she received a $1,000,000 retention bonus payable in three tranches through April 2029. The filing reflects standard executive compensation changes and does not indicate any negative or flat performance metrics.

• · Laura Cockrill was appointed CFO effective June 22, 2026, previously serving as Chief Strategy Officer.
• · The retention bonus of $1,000,000 was approved prior to her CFO appointment and is paid in three tranches: $200,000 (April 2027), $300,000 (April 2028), and $500,000 (April 2029).
• · Long-term incentive awards for 2027 will be granted in a form and on terms to be approved by the Committee at that time.

09-07-2026

Biohaven Ltd. announced scientific leadership transitions, including the promotion of David Pirman, Ph.D. to EVP and Head of Discovery, and the retirement of Bruce Car, Ph.D. as Chief Scientific Officer to a part-time Chief Innovation Officer role effective July 13, 2026. Warren Volles, General Counsel, was also designated an executive officer. The changes aim to accelerate drug innovation and external collaborations, particularly the Bexorg partnership, but represent a loss of a full-time CSO and a shift to part-time leadership.

• · Dr. Car will remain as a part-time employee in the newly created role of Chief Innovation Officer, effective July 13, 2026.
• · Dr. Car will focus on external collaborations, including leading multiple assets under the Bexorg collaboration.
• · Warren Volles has been designated an executive officer of Biohaven.
• · The Bexorg collaboration was announced in June 2025 and uses Bexorg's whole-brain discovery platform for CNS therapies.

09-07-2026

Travere Therapeutics announced the planned retirement of Chief Accounting Officer Sandra Calvin following the filing of the 2026 Annual Report (expected February 2027). Vice President, Controller John Torell, CFA, CPA, is expected to succeed her as CAO and PAO, with an orderly transition planned in advance of her retirement date.

• · Sandra Calvin's retirement is effective following the filing of the Annual Report on Form 10-K expected in February 2027.
• · John Torell has been with Travere since 2021, serving as Vice President, Controller since 2023, and previously held finance leadership roles at Pacific Life Insurance Company (1997-2019) and was an Audit Manager at Deloitte.
• · John Torell holds a B.A. in Economics-Business from UCLA and is both a CFA and CPA.

09-07-2026

Nixxy, Inc. announced the resignation of CEO Mike Schmidt effective July 2, 2026, with no disagreement with the company, and the appointment of board member David Kratochvil as the new CEO. Kratochvil, 60, brings over 30 years of Wall Street experience and will receive an annual base salary of $180,000 plus an equity award of 100,000 stock units. Separately, the company regained compliance with Nasdaq's minimum bid price requirement after its stock closed at $1.00 or above for 10 consecutive business days through July 1, 2026, though it cautioned that future compliance is not assured.

• · David Kratochvil holds an MBA in finance and international business from the University of Chicago Booth School of Business and a BS in Economics from the Wharton School.
• · Kratochvil holds FINRA Series 7, 14, 24, 63, 79, 86 and 87 registrations.
• · If Kratochvil is terminated without cause after the first 90 days, he receives one month of base salary and health insurance benefits.
• · Upon a change of control, any unvested stock units accelerate; if terminated without cause or material role change in connection with change of control, he receives four months of base salary.
• · The company had previously disclosed a Nasdaq non-compliance notice on February 20, 2026, for failing the minimum bid price requirement.

09-07-2026

Vera Therapeutics announced that William Turner will step down as Chief Regulatory Officer effective August 3, 2026, transitioning to Special Advisor for Regulatory Affairs. Nancy Bowman, M.D., Ph.D., will succeed him as Chief Regulatory Officer on the same date. The filing contains no financial data or performance metrics.

• · William Turner's transition to Special Advisor for Regulatory Affairs is effective August 3, 2026.
• · Nancy Bowman, M.D., Ph.D., will become Chief Regulatory Officer effective August 3, 2026.

09-07-2026

John Wiley & Sons appointed Frank Scognamiglio as Corporate Vice President, Chief Accounting Officer, effective July 9, 2026, succeeding Christopher Caridi. Caridi will remain with the company as Senior Vice President, Business Transformation until his expected retirement on April 30, 2027. The appointment reflects a routine leadership transition in the finance function.

• · Frank Scognamiglio, age 52, previously served as Corporate Vice President, Global Controller since April 2025 and before that as Corporate Vice President, Global Financial Shared Services.
• · The restricted share units award vests in three equal annual installments on June 30, 2027, 2028, and 2029.
• · No family relationships or transactions requiring disclosure under Regulation S-K Items 401(d) or 404(a) were noted.

09-07-2026

Central Plains Bancshares appointed Dannel R. Garness and Francis Younes to its Board of Directors on July 7, 2026. The appointment of Mr. Younes follows a shareholder activist proposal from the Stilwell Group, which had sought to nominate a director and push for a mandatory annual stock buyback of at least 10% of outstanding shares when the stock trades below book value. The company resolved the activist matter by appointing the nominee, but the buyback proposal remains an open item for the 2026 Annual Meeting.

• · Mr. Garness is an employee director and will not receive director fees; his compensation is described in the 2025 proxy statement.
• · Mr. Younes will receive standard non-employee director compensation as described in the 2025 proxy statement.
• · Neither new director has any reportable related-party transactions under Item 404(a).
• · The Stilwell Group's buyback proposal will be presented at the 2026 Annual Meeting; the company has not yet indicated its position on the proposal.
• · The company is an emerging growth company and has not elected the extended transition period for new accounting standards.

09-07-2026

FibroBiologics appointed retired NASA astronaut and microbiologist Kathleen 'Kate' Rubins, Ph.D. to its Board of Directors, effective July 9, 2026. Dr. Rubins, who has served on the company's Scientific Advisory Board since 2022, brings expertise in space biomedicine and infectious disease research. The appointment strengthens the board's scientific credentials but does not involve any financial changes or operational updates.

• · Dr. Rubins was elected to the National Academy of Medicine in 2025.
• · She retired from NASA in 2025 after 16 years with the agency.
• · She became the first person to sequence DNA in space during her first mission.
• · FibroBiologics is a clinical-stage biotechnology company with a focus on chronic diseases using fibroblasts.

09-07-2026

Pure Cycle reported strong Q3 FY2026 results with total revenue of $8.2M (up 60% YoY) and net income of $2.9M (up 31% YoY), driven by growth across land development and water segments. However, the company is pausing further expansion of its single-family rental segment due to regulatory uncertainty, and cash & cash equivalents decreased to $8.4M from $8.4M (flat) as of August 31, 2025, reflecting significant investment in construction and infrastructure. Additionally, director Daniel R. Kozlowski resigned effective July 7, 2026.

• · Wastewater tap sales declined 8% for the nine months ended May 31, 2026 (117 vs 127 in prior year), while water tap sales increased 24% (161 vs 130).
• · Cash and cash equivalents remained flat at $8.4M as of May 31, 2026, with $10.0M undrawn working capital line of credit.
• · The company paused further expansion of its single-family rental segment beyond units currently under contract due to regulatory uncertainty.
• · Phase 2D is 84% complete, Phase 2C is 95% complete, and Phase 2E development has begun with 159 lots expected in fiscal 2027.
• · The company is selling a portion of reserved lots in Phases 2C and 2D to homebuilder customers instead of retaining them for rental.